Astellas Pharma (OTCMKTS:ALPMY) Issues Earnings Results, Beats Estimates By $0.15 EPS

Astellas Pharma (OTCMKTS:ALPMY) issued its quarterly earnings data on Wednesday. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.15, Zacks reports. The firm had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%.

Astellas Pharma Price Performance

ALPMY stock traded up $0.36 during trading hours on Thursday, hitting $15.73. 76,511 shares of the stock traded hands, compared to its average volume of 103,515. The stock has a 50-day simple moving average of $13.62 and a 200 day simple moving average of $11.98. The company has a market cap of $28.46 billion, a P/E ratio of 33.46 and a beta of 0.18. Astellas Pharma has a one year low of $8.37 and a one year high of $16.00. The company has a current ratio of 1.03, a quick ratio of 0.80 and a debt-to-equity ratio of 0.20.

Analyst Ratings Changes

ALPMY has been the topic of a number of recent analyst reports. Citigroup cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).